Innovassynth Investments Ltd
Incorporated in 2008, Innovassynth Investments Ltd is a holding and investment company
- Market Cap ₹ 195 Cr.
- Current Price ₹ 80.4
- High / Low ₹ 92.5 / 19.5
- Stock P/E
- Book Value ₹ 14.9
- Dividend Yield 0.00 %
- ROCE -1.25 %
- ROE -2.30 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 5.41 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 36.3%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Finance Industry: Finance & Investments
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.28 | 0.37 | 1.30 | 0.50 | 10.81 | |
| Operating Profit | -0.28 | -0.37 | -1.30 | -0.50 | -10.81 |
| OPM % | |||||
| 0.00 | 1.86 | 0.02 | 0.00 | 9.52 | |
| Interest | 0.24 | 0.27 | 0.30 | 0.34 | 0.39 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.52 | 1.22 | -1.58 | -0.84 | -1.68 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | |
| -0.52 | 1.22 | -1.58 | -0.84 | -1.68 | |
| EPS in Rs | -0.21 | 0.50 | -0.65 | -0.35 | -0.69 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -27% |
| TTM: | 74% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 69% |
| 3 Years: | 65% |
| 1 Year: | 209% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -2% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Equity Capital | 24.28 | 24.28 | 24.28 | |
| Reserves | 12.68 | 12.64 | 11.79 | |
| 2.85 | 3.24 | 3.59 | ||
| 0.94 | 1.22 | 1.56 | ||
| Total Liabilities | 40.75 | 41.38 | 41.22 | |
| 0.00 | 0.00 | 0.00 | ||
| CWIP | 0.00 | 0.00 | 0.00 | |
| Investments | 40.74 | 41.35 | 41.21 | |
| 0.01 | 0.03 | 0.01 | ||
| Total Assets | 40.75 | 41.38 | 41.22 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| -0.32 | -0.34 | -0.33 | ||
| 0.00 | 0.00 | 0.00 | ||
| 0.32 | 0.36 | 0.32 | ||
| Net Cash Flow | 0.00 | 0.02 | -0.01 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Debtor Days | ||||
| Inventory Days | ||||
| Days Payable | ||||
| Cash Conversion Cycle | ||||
| Working Capital Days | ||||
| ROCE % | -3.20% | -1.25% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
21h - Certificate under SEBI regulations for Q3 2024.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 3 Oct
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 3 Oct
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 1 Oct
-
Closure of Trading Window
1 Oct - Closure of trading window until financial results announcement.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Associate:[1][2][3]
Company invested in Innovassynth Technologies (India) Limited (~31.79%), which is its Associate from 12 February 2022. ITIL is R&D and technology-based Organization engaged in developing, scaling up and manufacturing of specialty chemicals and pharmaceutical Intermediates. Key focus business areas are customs synthesis, contract research & manufacturing of specialty chemicals, toll manufacture of chemicals and similar businesses. It also supplies protected nucleosides and modified phosphonamidites used for clinical, diagnostic and therapeutic oligonucleotides applications. On 12th February 2022, Managing Director of Innovassynth Technologies Ltd was appointed as Managing Director of company resulting into establishment of significant influence over ITIL. Company has not diversified its investment in other entities except ITIL